In contrast to the broader stock market and many fellow healthcare companies, Pfizer stock had a fine Wednesday.
Pfizer has numerous tailwinds going for it, not least its continued leading position in the fight against COVID-19.
Meanwhile, on Wednesday Pfizer announced a potentially big advancement in another major segment of healthcare, oncology.
In late August, Pfizer revealed it had struck a deal to acquire the company for $2.26 billion in cash.
It said on Wednesday that Frank D’Amelio — who also serves as the company’s executive vice president of global supply — is exiting after nearly 15 years in its ranks.
To sum, Pfizer’s latest developments include the closing of a deal for a highly complementary asset, and a smooth transition in the upper managerial ranks.